Pharmacokinetics and Safety of Topical Administration of Brimonidine Tartrate Ophthalmic Solution 0.025%.
Status:
Completed
Trial end date:
2014-04-01
Target enrollment:
Participant gender:
Summary
To characterize the plasma pharmacokinetics and safety profile of brimonidine following a
single dose and 4 times per day (QID) dosing of brimonidine tartrate ophthalmic solution
0.025% for 7 days in healthy, adult subjects.